Novantrone is a brand name for Mitoxantrone.
Novantrone belongs to the general group of medicines called antineoplastics. Prior to its approval for use in Multiple Sclerosis, it was used only to treat certain forms of cancer. It acts in MS by suppressing the activity of T cells, B cells, and macrophages that are thought to lead the attack on the myelin sheath.
The use of Novantrone for the treatment of MS has been evaluated in a series of European studies over a period of ten years. In a recent randomized, placebo-controlled, multi-center clinical trial involving patients with secondary-progressive or progressive-relapsing disease. Novantrone was found to delay the time to first treated relapse and time to disability progression. It also reduced the number of treated relapses and number of new lesions detected by MRI.
Based on findings from these studies, the FDA approved Novantrone in October, 2000 for reducing neurologic disability and/or the frequency of clinical relapses (attacks) in:
- Patients with secondary progressive Multiple Sclerosis (disease that has changed from relapsing-remitting to progressive at a variable rate)
- Progressive-relapsing MS (disease characterised by gradual increase in disability from onset with clear, acute relapses along the way);
- Worsening relapsing-remitting MS (disease characterised by clinical attacks without complete remission, resulting in a step-wise worsening of disability.
Possible Side-Effects
- Nausea
- Hair Loss
- Menstrual Disorder
- Fever or Chills
- Shortness of Breath
This site is hosted by names.co.uk and the domain name has been registered with them. I have found them to be reasonably priced, helpful and reliable. So, if you are looking for domain name registration or web site hosting, click the above banner.
